You are here

Psoriasis Drug Tildrakizumab Scores in Two Pivotal Trials

Monoclonal antibody increases skin clearance

Tildrakizumab (Sun Pharma), an investigational interleukin (IL)-23p19 inhibitor, has achieved its primary endpoint in two pivotal phase 3 studies (reSURFACE 1 and 2) involving patients with moderate-to-severe plaque psoriasis. An average of 63% of patients showed 75% skin clearance (Psoriasis Area Sensitivity Index [PASI] 75) by week 12 after two injections of tildrakizumab 100 mg, and 77% showed PASI 75 after 28 weeks and three injections.

Similarly, an average of 57% and 66% of patients had a Physician’s Global Assessment (PGA) score of “clear” or “minimal” with the 100-mg dose at weeks 12 and 28, respectively. In addition, 64% and 78% of patients treated with a 200-mg dose of tildrakizumab achieved PASI 75 at weeks 12 and 28, respectively, and 59% and 69% had PGA scores of “clear” or “minimal” at those time points.

The data further showed that a higher number of patients receiving tildrakizumab achieved PASI 90 and PASI 100 compared with placebo and etanercept. An average of 37% and 36% of patients treated with tildrakizumab achieved PASI 90 at week 12 with the 100-mg and 200-mg doses, respectively, which increased to 54% and 59% at week 28. Moreover, an average of 13% of those receiving tildrakizumab achieved PASI 100 at week 12 regardless of the dose, with increases to 24% for the 100 mg-dose and to 30% for the 200-mg dose at week 28.

In both trials, the rates of severe infections, malignancies, and extended major cardiovascular events (MACE) were low and similar across treatment groups (1% to 3%).

Tildrakizumab is an investigational humanized, anti–IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23.

Source: Sun Pharma; October 1, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs